The effect of imatinib on chlorambucil (CLB) cytotoxicity in chronic lymphocytic leukemia (CLL) lymphocytes was examined in vitro. Imatinib sensitizes the WSU and I83 human CLL cell lines, 10-and two-fold, respectively, to CLB. Furthermore, in primary cultures of malignant B-lymphocytes obtained from 12 patients with CLL (seven patients were untreated and five treated with CLB), imatinib synergistically sensitized these lymphocytes from two-to 20-fold to CLB. This synergistic effect was observed at concentrations of imatinib (p10 lM), which are achievable in patients with minimal toxicity. Moreover, the combination of both drugs results in increased apoptosis in CLL cell lines. These results suggest that imatinib should be useful in improving the therapeutic index of CLB in CLL. The mechanism of action appears to involve imatinib inhibition of c-abl kinase activity with an associated decrease in CLB-induced Rad51 phosphorylation and CLB-induced Rad51 nuclear foci, suggesting that imatinib decreases Rad51-related DNA repair of CLB-induced DNA lesions. Altogether, our results suggest that imatinib is a promising adjuvant therapy to CLB treatment of CLL. Leukemia (2004) 
Introduction
Chronic lymphocytic leukemia (CLL) is leukemia of immature Blymphocytes, which accumulate in the blood of affected patients. CLL is an excellent malignancy for in vitro studies for the reason that there is a strong correlation between in vitro cytotoxicity of chlorambucil (CLB) (as measured by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay) and in vivo response in CLL patients. 1 In CLL lymphocytes and multiple myeloma, drug sensitivity is determined in part by repair capacity of nitrogen mustard-induced DNA interstrand crosslinks (ICLs). [2] [3] [4] [5] We have demonstrated that a mechanism of DNA crosslinking agent drug resistance implicates proficient Rad51-related homologous recombinational repair (HRR) in clinical specimens (CLL samples). 6, 7 The HRR repair process is positively regulated after DNA damage by the activation of the c-abl nonreceptor tyrosine kinase, which results in Rad51 phosphorylation. 8, 9 In myeloid-engineered cell lines, Rad51 phosphorylation mediates drug resistance. 10, 11 Imatinib is an inhibitor of BCR/ABL, c-abl, c-kit and PDGFR. 12 Imatinib is currently used as a first-line treatment of chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia. 13, 14 Moreover, in vitro studies indicate that imatinib may be used in combination with other chemotherapeutic agents to improve CML treatment. While the mechanism involved has not been addressed yet, imatinib used in combination with drugs that interfere with DNA metabolism have a synergistic cytotoxic effect in primary CML cells. 15, 16 Virtually all CML cases express a constitutively active c-abl kinase as a consequence of the t(9, 22) (q34, 11) translocation. In contrast in CLL patients, BCR/ABL translocations have not been reported. Whereas the biological process involved in the transforming capacity of BCR/ABL has been extensively characterized, the biological function of c-abl is less understood. BCR/ABL inhibits apoptosis in myeloid cells exposed to DNA damage, cytokine deprivation and Fas activation. 17 Several lines of evidence suggest a positive role of c-abl in cell cycle regulation and genotoxic stress signaling. In some cell types, it has been demonstrated that c-abl activation is required for DNA damage-induced apoptosis. 18 In contrast, cabl knockout mice display abnormalities in lymphoid cells such as splenic and thymic atrophy plus lymphopenia. 19 Moreover, c-abl null progenitor B-cell lines are more sensitive to apoptotic stimuli than wild-type cells. 20 Thus, it appears that c-abl may play an antiapoptotic or proapoptotic function depending on the cell type and cellular context.
In view of the fact that: (a) c-abl positively regulates Rad51-related HRR of CLB-induced -lesions, 10, 11 and (b) HRR is implicated in CLB drug resistance in CLL, [6] [7] we investigated the effect of the c-abl inhibitor imatinib on CLB cytotoxicity in CLL lymphocytes. 12 
Materials and methods

Patients
In all, 12 patients with a diagnosis of B-CLL followed at the Jewish General Hospital of Montreal were enrolled in the study after informed consent. Patients were either untreated (n ¼ 7) or treated with CLB (n ¼ 5) for various time periods.
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Cytotoxicity assay
Lymphocytes were isolated from the peripheral blood using Ficoll-Hypaque (Pharmacia, Uppsala, Sweden) as described. 6 The T-lymphocyte contamination in the isolated B-lymphocytes population was 6.471.8 (expressed as a mean%7s.e. and determined by FACS analysis). The CLL lymphocytes (1.5 Â 10 6 cells/ml) and the CLL cell lines (1.5 Â 10 5 cells/ml), WSU 24 and I83, 25 were plated in RPMI 1640 supplemented with 10% fetal bovine serum (FBS) and incubated in the presence of various concentrations (0-100 mM) of imatinib alone (generously provided by Novartis), CLB (Sigma) alone or in combination as indicated. The MTT assay was performed 72 h after treatment as described earlier. 6, 7, 21 Synergy was determined by the formula: a/A þ b/B ¼ I, where a is the CLB IC 50 (the concentration that results in 50% of control) obtained in combination with imatinib at concentration b; A is the CLB IC 50 without imatinib; and B is the imatinib IC 50 in the absence of CLB. According to the formula, when Io1, the interaction is synergistic, when I ¼ 1, the interaction is additive, and when I41 there is an antagonistic interaction. 21 Cell cycle analysis I83 and WSU cells were plated in RPMI 10% FBS (1.5 Â 10 5 /ml) and treated with vehicle, CLB, imatinib or the combination of both drugs. Cell cycle progression was analyzed as described earlier. 26 Briefly, the cells were harvested at 72 h, fixed with icecold 70% ethanol, and the DNA was stained with 50 mg/ml propidium iodide and 0.02 mg/ml DNase-free RNase A for 5 min, washed with phosphate-buffered saline (PBS), and stored in the dark at 41C for no longer than 8 h. Cell cycle analysis was performed using a FACSCalibur flow cytometer (Becton Dickinson).
Annexin V assay
I83 and WSU cells were plated in RPMI 10% FBS (1.5 Â 10 5 /ml) and treated with vehicle, CLB, imatinib or the combination of both drugs for 60 h. The cells (1 Â 10 5 cells) were harvested, washed with PBS, stained with Annexin V-EGFP (Clontech) and 7-AAD (BD Pharmingen) following the manufacturer's instructions and immediately subjected to bivariate analysis using a FACSCalibur flow cytometer (Becton Dickinson).
Rad51 and c-abl phosphorylation analysis
Rad51 and c-abl Tyr-phosphorylation was assessed as described earlier. 8, 10, 27 Briefly, I83 and WSU CLL cell cultures were treated with drugs for 6 h and lysed (20 mM Tris, 135 mM NaCl, 1% NP-40, 10% glycerol, Roche protease inhibitors and 1 mM Na vanadate). Protein extracts (1.5 mg for Rad51 and 5 mg for c-abl) were incubated with a monoclonal-a-Rad51 or monoclonal-a-c-abl-specific antibodies (Santa Cruz); the immunoprecipitates were collected using PG-sepharose (Sigma), separated by 12% SDS-PAGE, transferred onto nitrocellulose and probed with a specific monoclonal a-phosphotyrosine (p-Tyr) antibody (4G10 1/10 000, Upstate Biotech). After stripping, the membranes were reprobed with a polyclonal-aRad51 and a polyclonal a-c-abl (Santa Cruz). The ratio between the p-Tyr signal and the Rad51 or c-abl signals (analyzed using the Scion Image software) were calculated for each sample and normalized to the corresponding control ratio.
Rad51 Foci determination
I83 and WSU cells were treated with vehicle, CLB IC 50 , imatinib IC 50 or the combination of both drugs for 4 h. Aliquots (100 ml) of the cell suspension were centrifuged onto clean glass slides at 1000 r.p.m. for 10 min in a cytospin (Hettich). Rad51 foci density was determined as described earlier. 6, 27 Briefly, after cytocentrifugation, the slides were fixed in methanol:acetone (1:1 v/v) for 10 min at À201C. After three washes with PBS (pH 7.4), the nuclei were stained with propidium iodide 5 mg/ml and RNase at a concentration of 2.5 mg/ml for 5 min. After three PBS washes, the slides were incubated for 1 h in blocking solution (PBS (pH 7.4), 3% BSA fraction V; Sigma) followed by overnight incubation at 41C with an a-Rad51 antibody (Upstate Biotechnology) 1:250 in blocking solution. The slides were washed with several changes of PBS for 10 min at room temperature and then incubated for 1 h with CY2-conjugated secondary antibody (Jackson Laboratories) diluted 1:300 in blocking solution. After PBS washes, the slides were mounted using Sigma mounting medium and analyzed by microscopy. The images were captured using a Zeiss microscope and acquired into a computer using the Spot and Image Plus software. The images were merged electronically with yellow staining representing the merging of the red (propidium iodide) and green labeling (CY2), indicating Rad51 in the nuclear localization. To quantify the total Rad51 foci density, we determined the ratio of the average yellow pixel intensity relative to the total yellow stained nuclear area in 10 randomly selected nuclei for each treatment.
Statistical analysis
Differences between mean values were assessed by two-tailed t-test. Linear regression and correlation analyses were performed using the EXCEL Statistical Tool Package. Results are expressed as a mean value7s.d.
Results and discussion
Imatinib synergistically sensitizes CLL cells to CLB
Experiments performed with the WSU and I83 cell lines (Table 1) using the MTT assay show that imatinib synergistically sensitized these cells to CLB cytotoxicity 10-and two-fold, respectively. Incubations of WSU cells with CLB alone required a concentration of 34 mM to produce an IC 50 , while 13.73 mM imatinib alone produced an IC 50 . However, incubations with both drugs simultaneously resulted in an IC 50 of 5.95 mM for CLB in the presence of 5.0 mM imatinib (I ¼ 0.53) and 3.15 mM in the presence of 10 mM imatinib (I ¼ 0.82). Incubations of I83 cells with CLB alone required a concentration of 40.66 mM to produce an IC 50 , while 33.72 mM imatinib alone produced an IC 50 . Concentration of imatinib (mM) utilized in combination with CLB. 
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C-abl inhibition synergistically increases CLB-induced apoptosis in CLL cells
To determine if the reduction (induced by imatinib alone or in combination with CLB) in metabolic activity measured by MTT assay is the result of a phase-specific cell cycle arrest, generalized downregulation of DNA turnover or cell death, we analyzed changes in cell cycle progression of I83 and WSU treated cells. Our results indicate that imatinib (0-20 mM) induces cell death 72 h after treatment (Figure 1a and b) . In agreement with the earlier reports demonstrating that c-abldeficient mice display abnormalities in lymphoid cells such as splenic and thymic atrophy and lymphopenia, 19 our results demonstrate that c-abl inhibition results in B-lymphocytes death. As reported earlier, CLB treatment (0-9 mM) induces G2/ M arrest and cell death (sub-G1 cells with DNA contents p2) (Figure 1c and d) . 28 When CLB (3 mM) was used in combination with 5 mM imatinib, a concentration that does not affect cell cycle progression, the percentage of sub-G1 cells 72 h after treatment was higher with the addition of the percentage of sub-G1 cells observed with CLB or imatinib alone in both cell lines (Figure 1e and f) . To determine whether or not apoptosis or necrosis was induced, Annexin V staining was used to detect early apoptosis 60 h after drug treatment (Figure 1g and  h ). Our results demonstrate that imatinib synergistically sensitizes CLL cells to CLB-induced apoptosis. As assessed by FACS analysis using specific antibodies, WSU and I83 cells do not express c-kit or PDGF-R (data not shown), suggesting that the synergistic effect of imatinib is mediated by c-abl inhibition. To confirm this hypothesis, we assess indirectly the c-abl kinase activity in untreated and treated CLL cells. As it has been demonstrated that c-abl autophosphorylation status correlates with c-abl kinase activity, we determined c-abl tyrosine phosphorylation in protein extracts by Western blot. 29 WSU and I83 cells were treated with vehicle, CLB IC 50 , imatinib IC 50 or the combination of both drugs for 6 h. Our results (Figure 2a and b) indicate that: (1) CLB significantly induces c-abl phosphorylation (I83 cells, P ¼ 0.009 and WSU cells P ¼ 0.04); and (2) imatinib significantly inhibits basal c-abl phosphorylation (I83 cells, P ¼ 0.04 and WSU cells P ¼ 0.04) and
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Figure 2
After plating WSU (a, c and e) and I83 (b, d and f), cells were maintained in complete medium or treated with vehicle, 34.0 mM CLB, 13.0 mM imatinib (WSU cells) or 40 mM CLB, 33.0 mM imatinib (I83 cells) or the combination of both drugs. c-Abl (a and b) and Rad51 phosphorylation (c and d) were determined 6 h later by immunoprecipitation followed by Western blot analysis as described in Materials and methods. The plots represent the level of phosphorylation after treatment, normalized to the control value. The y-axis represents the c-abl or Rad51 p-Tyr signal normalized to the control value (vehicle treated cells) and the x-axis represents the treatment, control (0), CLB, imatinib or CLB þ imatinib at the concentrations indicated above. The effect of imatinib in CLB-induced Rad51 foci formation was determined as described in Material and methods. The images are representative images of two independent experiments of control (left picture)-, CLB (middle picture)-or CLB þ imatinib (right picture)-treated I83 (e) and WSU (f) cells for 4 h. The histograms represent the Rad51 foci density for each treatment. The Rad51 foci density of CLB-treated cells was compared to Rad51 foci density of vehicle (0) or CLB þ STI-treated cells. The values represent the mean of two independent experiments7s.d. Significant differences between mean values was assessed using the Student's t-test, n Po0.05 and nn Po0.01. 
Imatinib sensitizes primary CLL lymphocytes to CLB
To further evaluate the effect of imatinib in CLB cytotoxicity, in vitro studies were performed in lymphocytes from CLL patients utilizing the MTT assay. The patients were categorized as follows in Table 2 ; seven patients were untreated (U 1 -U 7 ) and five patients had been previously treated with CLB (T 1 -T 5 ). The results indicate that out of the seven untreated patients, six showed synergistic effects with imatinib (U 1 -U 6 ), while one patient (U 7 ) showed antagonistic results (I ¼ 5.93). All five of the patients who had been previously treated with CLB (T 1 -T 5 ) showed synergistic effects. The CLB IC 50 alone ranged from 5.56 to 79.7 mM. The imatinib IC 50 alone ranged from 16.5 to 101.8 mM. Imatinib (5-10 mM) decreased the concentration of CLB necessary to produce an IC 50 to 1.1-59.0 mM.
We did not find a correlation between the IC 50 of imatinib and the IC 50 of CLB, indicating that imatinib sensitizes CLL lymphocytes to CLB regardless of the sensitivity of CLB. The only significant correlation between the parameters determined, shown in Table 2 , was the CLB IC 50 alone vs CLB IC 50 in the presence of 5 mM imatinib (r ¼ 0.90, P ¼ 0.0001). The lack of correlation between CLB IC 50 and imatinib IC 50 indicates that the two drugs mediate their cytotoxicity through different signaling pathways when used alone. Nevertheless, when used together c-abl inhibition alters CLB cytotoxicity (possibly by modulating DNA repair). The strong correlation between the CLB IC 50 and CLB IC 50 in the presence of imatinib suggest that upon CLB-mediated DNA damage, c-abl is an activated target that imatinib can inhibit. In agreement with this, both drugs act synergistically in 11 out of 12 patients. The fact that the sensitization obtained using 5 and 10 mM imatinib is similar indicates that synergy between both drugs appears not to be dose dependent. This may be due to the maximal inhibition of cabl kinase at p5 mM in patient samples. Imatinib pharmacokinetics demonstrate that after oral administration to patients, the C max (maximum concentration) occurs at 1-3 h after administration. The C max after a 400 mg dose is 2.3571.0 mg/ml (E4.0 mM) and after a 600 mg dose is 7.8373.8 mg/ml (E13.0 mM). The half-life is approximately 12 h. 30, 31 Thus, the concentrations (p10 mM) of imatinib utilized in our experiments are clinically obtainable.
Imatinib decreases CLB-induced Rad5I phosphorylation and Rad51 foci density in CLL cells
It has been shown that activated c-abl enhances complex formation between Rad51 and Rad52, 8 which stimulate homologous pairing. 32 Furthermore, the expression of BCR/ABL in myeloid cells increases the Rad51-related response to DNA damage, resulting in resistance to DNA crosslinking agents. 10, 11 These previous studies taken together with the results reported here led us to hypothesize that upon DNA damage, HRR is activated by c-abl-mediated Rad51 phosphorylation; imatinib would, then, inhibit c-abl-mediated DNA repair decreasing the survival of treated cells. Since imatinib has been shown to inhibit Rad51 phosphorylation in myeloid cells, 10 we examined the effect of imatinib on CLB-induced Rad51 phosphorylation in CLL cells. WSU and I83 cells were plated, treated with vehicle, CLB IC 50 , imatinib IC 50 or the combination of both drugs, following which Rad51 phosphorylation and Rad51 foci density were determined. Our results demonstrate that imatinib significantly inhibits CLB-induced Rad51 phosphorylation (I83 cells P ¼ 0.045; WSU cells P ¼ 0.001) (Figure 2c and d) and Rad51 foci density (I83 cells P ¼ 0.04; WSU cells P ¼ 0.01) after treatment in both WSU and I83 cells (Figure 2 e and f) .
Conclusions
The results reported here demonstrate that: (a) imatinib induces apoptosis in CLL cells, (b) imatinib synergistically sensitizes CLL cells to CLB at clinically obtainable concentrations (p10 mM) and (c) imatinib sensitizes CLL lymphocytes to CLB via the inhibition of c-abl kinase that results in decreased CLB-induced Rad51 phosphorylation and decreased HRR as measured by Rad51 foci density. The fact that imatinib sensitizes CLL cells to CLB at concentrations clinically obtainable suggests that imatinib may improve the therapeutic index of CLB in CLL. 
